Yokukansan, a traditional Japanese medicine, enhances the L-DOPAInduced rotational response in 6-hydroxydopamine-lesioned rats: Possible inhibition of COMT

Biological and Pharmaceutical Bulletin

Volumn 39, Issue 1, 2016, Pages 104-113

  Ishida, Yasushi ^a   Ebihara, Kosuke ^a   Tabuchi, Masahiro ^b   Imamura, Sachiko ^b   Sekiguchi, Kyoji ^b   Mizoguchi, Kazushige ^b   Kase, Yoshio ^b   Koganemaru, Go ^a   Abe, Hiroshi ^a,c   Ikarashi, Yasushi ^b  

^a UNIVERSITY OF MIYAZAKI   (Japan)

^b TSUMURA AND CO   (Japan)

^c HEALTH SCIENCES UNIVERSITY OF HOKKAIDO   (Japan)

Author keywords

4 dihydroxyphenylalanine (L DOPA); 6 hydroxydopamine; Abnormal involuntary movement; Catechol O methyltransferase; Dopamine; L 3; Yokukansan

Indexed keywords

3 HYDROXYBENZYLHYDRAZINE; 3 O METHYLDOPAMINE; ALKALOID; ANGELICA ACUTILOBA EXTRACT; ATRACTYLODES EXTRACT; BENSERAZIDE; BUPLEURUM ROOT EXTRACT; CATECHOL METHYLTRANSFERASE; CNIDIUM RHIZOME EXTRACT; CORYNOXEINE; DOPAMINE; ENTACAPONE; GEISSOSCHIZINE METHYL ETHER; GLYCYRRHIZA URALENSIS EXTRACT; HIRSUTEINE; HIRSUTINE; ISOCORYNOXEINE; ISORHYNCHOPHYLLINE; LEVODOPA; OXIDOPAMINE; PARGYLINE; PLANT EXTRACT; PORIA COCOS EXTRACT; RHYNCHOPHYLLINE; SEROTONIN; TYROSINE 3 MONOOXYGENASE; UNCARIA RHYNCHOPHYLLA EXTRACT; UNCLASSIFIED DRUG; 3-HYDROXYBENZYLHYDRAZINE; 3-METHOXYTYRAMINE; CATECHOL DERIVATIVE; HERBACEOUS AGENT; HYDRAZINE DERIVATIVE; NITRILE; YI-GAN SAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN DAMAGE; CIRCLING BEHAVIOR; CONTROLLED STUDY; DOPAMINE METABOLISM; DYSKINESIA; ENZYME INHIBITION; FORELIMB; IMMUNOREACTIVITY; LIMB MOVEMENT; MALE; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; RAT; SEROTONINERGIC NERVE CELL; TRADITIONAL MEDICINE; UNCARIA; UNCARIA RHYNCHOPHYLLA; ANALOGS AND DERIVATIVES; ANIMAL; CELL LINE; CORPUS STRIATUM; DRUG EFFECTS; ORIENTAL MEDICINE; WISTAR RAT;

ANIMALS; BENSERAZIDE; CATECHOLS; CELL LINE; CORPUS STRIATUM; DOPAMINE; DRUGS, CHINESE HERBAL; HYDRAZINES; LEVODOPA; MALE; MEDICINE, EAST ASIAN TRADITIONAL; NITRILES; OXIDOPAMINE; PARGYLINE; RATS; RATS, WISTAR;

EID: 84954522858     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b15-00691     Document Type: Article

References (54)

1. Hayashi Y, Ishida Y, Inoue T, Udagawa M, Takeuchi K, Yoshimuta H, Kiue K, Ninomiya Y, Kawano J, Sameshima T, Kawahara T, Goto I, Shudo K, Kurayama S, Nakamura J, Okahara K, Mitsuyama Y. Treatment of behavioral and psychological symptoms of Alzheimer's-Type dementia with Yokukansan in clinical practice. Prog. Neuropsychopharmacol. Biol. Psychiatry, 34, 541-545 (2010).
2. Matsuda Y, Kishi T, Shibayama H, Iwata N. Yokukansan in the treatment of behavioral and psychological symptoms of dementia: A systematic review and meta-Analysis of randomized controlled trials. Hum. Psychopharmacol., 28, 80-86 (2013).
3. Okahara K, Ishida Y, Hayashi Y, Inoue T, Tsuruta K, Takeuchi K, Yoshimuta H, Kiue K, Ninomiya Y, Kawano J, Yoshida K, Noda S, Tomita S, Fujimoto M, Hosomi J, Mitsuyama Y. Effects of Yokukansan on behavioral and psychological symptoms of dementia in regular treatment for Alzheimer's disease. Prog. Neuropsychopharmacol. Biol. Psychiatry, 34, 532-536 (2010).
4. Iwasaki K, Maruyama M, Tomita N, Furukawa K, Nemoto M, Fujiwara H, Seki T, Fujii M, Kodama M, Arai H. Effects of the traditional Chinese herbal medicine Yi-Gan San for cholinesterase inhibitor-resistant visual hallucinations and neuropsychiatric symptoms in patients with dementia with Lewy bodies. J. Clin. Psychiatry, 66, 1612-1613 (2005).
5. Iwasaki K, Kosaka K, Mori H, Okitsu R, Furukawa K, Manabe Y, Yoshita M, Kanamori A, Ito N, Wada K, Kitayama M, Horiguchi J, Yamaguchi S, Takayama S, Fukuhara R, Ouma S, Nakano S, Hashimoto M, Kinoshita T. Improvement in delusions and hallucinations in patients with dementia with Lewy bodies upon administration of yokukansan, a traditional Japanese medicine. Psychogeriatrics, 12, 235-241 (2012).
6. Hatano T, Hattori N, Kawanabe T, Terayama Y, Suzuki N, Iwasaki Y, Fujioka T, Yokukansan Parkinson's Disease Study Group. An exploratory study of the efficacy and safety of yokukansan for neuropsychiatric symptoms in patients with Parkinson's disease. J. Neural Transm., 121, 275-281 (2014).
7. Kawanabe T, Yoritaka A, Shimura H, Oizumi H, Tanaka S, Hattori N. Successful treatment with Yokukansan for behavioral and psychological symptoms of Parkinsonian dementia. Prog. Neuropsychopharmacol. Biol. Psychiatry, 34, 284-287 (2010).
8. Kanno H, Sekiguchi K, Yamaguchi T, Terawaki K, Yuzurihara M, Kase Y, Ikarashi Y. Effect of yokukansan, a traditional Japanese medicine, on social and aggressive behaviour of para-chloroamphetamine-injected rats. J. Pharm. Pharmacol., 61, 1249-1256 (2009).
9. Nishi A, Yamaguchi T, Sekiguchi K, Imamura S, Tabuchi M, Kanno H, Nakai Y, Hashimoto K, Ikarashi Y, Kase Y. Geissochizine methyl ether, an alkaloid in Uncaria hook, is a potent serotonin1A receptor agonist and candidate for amelioration of aggressiveness and sociality by yokukansan. Neuroscience, 207, 124-136 (2012).
10. Sekiguchi K, Yamaguchi T, Tabuchi M, Ikarashi Y, Kase Y. Effects of yokukansan, a traditional Japanese medicine, on aggressiveness induced by intracerebroventricular injection of amyloid β protein into mice. Phytother. Res., 23, 1175-1181 (2009).
11. Mizoguchi K, Shoji H, Tanaka Y, Tabira T. Ameliorative effect of traditional Japanese medicine yokukansan on age-related impairments of working memory and reversal learning in rats. Neuroscience, 177, 127-137 (2011).
12. Schwarting RK, Huston JP. Unilateral 6-hydroxydopamine lesions of meso-striatal dopamine neurons and their physiological sequelae. Prog. Neurobiol., 49, 215-266 (1996).
13. Ebihara K, Ishida Y, Takeda R, Abe H, Matsuo H, Kawai K, Magata Y, Nishimori T. Differential expression of FosB, c-Fos, and Zif268 in forebrain regions after acute or chronic L-DOPA treatment in a rat model of Parkinson's disease. Neurosci. Lett., 496, 90-94 (2011).
14. Papathanou M, Jenner P, Iravani M, Jackson M, Stockwell K, Strang I, Zeng BY, McCreary AC, Rose S. The H3 receptor agonist immepip does not affect L-dopa-induced abnormal involuntary movements in 6-OHDA-lesioned rats. Eur. J. Pharmacol., 741, 304-310 (2014).
15. Sgroi S, Kaelin-Lang A, Capper-Loup C. Spontaneous locomotor activity and L-DOPA-induced dyskinesia are not linked in 6-OHDA parkinsonian rats. Front. Behav. Neurosci., 8, 331 (2014).
16. Maeda T, Kannari K, Shen H, Arai A, Tomiyama M, Matsunaga M, Suda T. Rapid induction of serotonergic hyperinnervation in the adult rat striatum with extensive dopaminergic denervation. Neurosci. Lett., 343, 17-20 (2003).
17. Maeda T, Nagata K, Yoshida Y, Kannari K. Serotonergic hyperinnervation into the dopaminergic denervated striatum compensates for dopamine conversion from exogenous administered L-DOPA. Brain Res., 1046, 230-233 (2005).
18. Maeda T, Nagata K, Yoshida Y. Exogenous L-DOPA induce no dopamine immuno-reactivity in striatal astroglias and microglias of adult rats with extensive nigro-striatal dopaminergic denervation. Neurosci. Lett., 433, 255-258 (2008).
19. Arai R, Karasawa N, Nagatsu I. Aromatic L-Amino acid decarboxylase is present in serotonergic fibers of the striatum of the rat. A double-labeling immunofluorescence study. Brain Res., 706, 177-179 (1996).
20. Yamada H, Aimi Y, Nagatsu I, Taki K, Kudo M, Arai R. Immunohistochemical detection of L-DOPA-derived dopamine within serotonergic fibers in the striatum and the substantia nigra pars reticulata in Parkinsonian model rats. Neurosci. Res., 59, 1-7 (2007).
21. Miller DW, Abercrombie ED. Role of high-Affinity dopamine uptake and impulse activity in the appearance of extracellular dopamine in striatum after administration of exogenous L-DOPA: studies in intact and 6-hydroxydopamine-Treated rats. J. Neurochem., 72, 1516-1522 (1999).
22. Tanaka H, Kannari K, Maeda T, Tomiyama M, Suda T, Matsunaga M. Role of serotonergic neurons in L-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats. Neuroreport, 10, 631-634 (1999).
23. Nozawa K, Kawabata-Shoda E, Doihara H, Kojima R, Okada H, Mochizuki S, Sano Y, Inamura K, Matsushime H, Koizumi T, Yokoyama T, Ito H. TRPA1 regulates gastrointestinal motility through serotonin release from enterochromaffin cells. Proc. Natl. Acad. Sci. U.S.A., 106, 3408-3413 (2009).
24. Mizukami K, Asada T, Kinoshita T, Tanaka K, Sonohara K, Nakai R, Yamaguchi K, Hanyu H, Kanaya K, Takao T, Okada M, Kudo S, Kotoku H, Iwakiri M, Kurita H, Miyamura T, Kawasaki Y, Omori K, Shiozaki K, Odawara T, Suzuki T, Yamada S, Nakamura Y, Toba K. A randomized cross-over study of a traditional Japanese medicine (kampo), yokukansan, in the treatment of the behavioural and psychological symptoms of dementia. Int. J. Neuropsychopharmacol., 12, 191-199 (2009).
25. König JFR, Klippel RA. The Rat Brain: A Stereotaxic Atlas of the Forebrain and Lower Parts of the Brain Stem. Williams and Wilkins, Baltimore (1963).
26. Nishino H, Hashitani T, Kumazaki M, Sato H, Furuyama F, Isobe Y, Watari N, Kanai M, Shiosaka S. Long-Term survival of grafted cells, dopamine synthesis/release, synaptic connections, and functional recovery after transplantation of fetal nigral cells in rats with unilateral 6-OHDA lesions in the nigrostriatal dopamine pathway. Brain Res., 534, 83-93 (1990).
27. Ungerstedt U. Striatal dopamine release after amphetamine or nerve degeneration revealed by rotational behavior. Acta Physiol. Scand. Suppl., 82 (S367), 49-68 (1971).
28. Ishida Y, Hashiguchi H, Todaka K, Kuwahara I, Ishizuka Y, Nakane H, Uchimura D, Nishimori T, Mitsuyama Y. Serotonergic activity in the rat striatum after intrastriatal transplantation of fetal nigra as measured by microdialysis. Brain Res., 788, 207-214 (1998).
29. Henry B, Crossman AR, Brotchie JM. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat. Exp. Neurol., 155, 204-220 (1999).
30. Yamaguchi T, Tsujimatsu A, Kumamoto H, Izumi T, Ohmura Y, Yoshida T, Yoshioka M. Anxiolytic effects of yokukansan, a traditional Japanese medicine, via serotonin 5-HT1A receptors on anxiety-related behaviors in rats experienced aversive stress. J. Ethnopharmacol., 143, 533-539 (2012).
31. Cenci MA, Lee CS, Björklund A. L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphinand glutamic acid decarboxylase mRNA. Eur. J. Neurosci., 10, 2694-2706 (1998).
32. Ikarashi Y, Sasahara T, Maruyama Y. Postmortem changes in catecholamines, indoleamines, and their metabolites in rat brain regions: prevention with 10-kW microwave irradiation. J. Neurochem., 45, 935-939 (1985).
33. Kurkela M, Siiskonen A, Finel M, Tammela P, Taskinen J, Vuorela P. Microplate screening assay to identify inhibitors of human catechol-O-methyltransferase. Anal. Biochem., 331, 198-200 (2004).
34. Lee CS, Cenci MA, Schulzer M, Björklund A. Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson's disease. Brain, 123, 1365-1379 (2000).
35. Cenci MA, Whishaw IQ, Schallert T. Animal models of neurological deficits: how relevant is the rat? Nat. Rev. Neurosci., 3, 574-579 (2002).
36. Arai R, Karasawa N, Geffard M, Nagatsu T, Nagatsu I. Immunohistochemical evidence that central serotonin neurons produce dopamine from exogenous L-DOPA in the rat, with reference to the involvement of aromatic L-Amino acid decarboxylase. Brain Res., 667, 295-299 (1994).
37. Spinnewyn B, Mautino G, Marin JG, Rocher MN, Grandoulier AS, Ferrandis E, Auguet M, Chabrier PE. BN82451 attenuates L-dopainduced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease. Neuropharmacology, 60, 692-700 (2011).
38. Carta M, Lindgren HS, Lundblad M, Stancampiano R, Fadda F, Cenci MA. Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats. J. Neurochem., 96, 1718-1727 (2006).
39. Marin C, Aguilar E, Bonastre M, Tolosa E, Obeso JA. Early administration of entacapone prevents levodopa-induced motor fluctuations in hemiparkinsonian rats. Exp. Neurol., 192, 184-193 (2005).
40. Napolitano A, Bellini G, Borroni E, Zörcher G, Bonuccelli U. Effects of peripheral and central catechol-O-methyltransferase inhibition on striatal extracellular levels of dopamine: A microdialysis study in freely moving rats. Parkinsonism Relat. Disord., 9, 145-150 (2003).
41. Stansley BJ, Yamamoto BK. L-DOPA-induced dopamine synthesis and oxidative stress in serotonergic cells. Neuropharmacology, 67, 243-251 (2013).
42. Uchida N, Egashira N, Iwasaki K, Ishibashi A, Tashiro R, Nogami A, Manome N, Abe M, Takasaki K, Mishima K, Takata J, Oishi R, Nishimura R, Fujiwara M. Yokukansan inhibits social isolation-induced aggression and methamphetamine-induced hyperlocomotion in rodents. Biol. Pharm. Bull., 32, 372-375 (2009).
43. Sekiguchi K, Kanno H, Yamaguchi T, Ikarashi Y, Kase Y. Ameliorative effect of yokukansan on vacuous chewing movement in haloperidol-induced rat tardive dyskinesia model and involvement of glutamatergic system. Brain Res. Bull., 89, 151-158 (2012).
44. Kato A, Fukutake J, Kizu H, Asano N, Adachi I. Inhibitory effects of Senkyu-chacho-san and Cnidii Rhizoma on catechol-O-methyltransferase. J. Trad. Med., 21, 34-38 (2004).
45. Imamura S, Tabuchi M, Kushida H, Nishi A, Kanno H, Yamaguchi T, Sekiguchi K, Ikarashi Y, Kase Y. The blood-brain barrier permeability of geissoschizine methyl ether in Uncaria hook, a galenical constituent of the traditional Japanese medicine yokukansan. Cell. Mol. Neurobiol., 31, 787-793 (2011).
46. Mizoguchi K, Kushida H, Kanno H, Igarashi Y, Nishimura H, Ikarashi Y, Kase Y. Specific binding and characteristics of geissoschizine methyl ether, an indole alkaloid of Uncaria hook, in the rat brain. J. Ethnopharmacol., 158 (Pt A), 264-270 (2014).
47. Hamaue N, Ogata A, Terado M, Tsuchida S, Yabe I, Sasaki H, Hirafuji M, Togashi H, Aoki T. Entacapone, a catechol-O-methyltransferase inhibitor, improves the motor activity and dopamine content of basal ganglia in a rat model of Parkinson's disease induced by Japanese encephalitis virus. Brain Res., 1309, 110-115 (2010).
48. Kurth MC, Adler CH. COMT inhibition: A new treatment strategy for Parkinson's disease. Neurology, 50 (Suppl. 5), S3-S14 (1998).
49. Tadaiesky MT, Dombrowski PA, Figueiredo CP, Cargnin-Ferreira E, Da Cunha C, Takahashi RN. Emotional, cognitive and neurochemical alterations in a premotor stage model of Parkinson's disease. Neuroscience, 156, 830-840 (2008).
50. Watt MJ, Burke AR, Renner KJ, Forster GL. Adolescent male rats exposed to social defeat exhibit altered anxiety behavior and limbic monoamines as adults. Behav. Neurosci., 123, 564-576 (2009).
51. Brozoski TJ, Brown RM, Rosvold HE, Goldman PS. Cognitive deficit caused by regional depletion of dopamine in prefrontal cortex of rhesus monkey. Science, 205, 929-932 (1979).
52. Bubser M, Schmidt WJ. 6-Hydroxydopamine lesion of the rat prefrontal cortex increases locomotor activity, impairs acquisition of delayed alternation tasks, but does not affect uninterrupted tasks in the radial maze. Behav. Brain Res., 37, 157-168 (1990).
53. Simon H, Scatton B, Moal ML. Dopaminergic A10 neurones are involved in cognitive functions. Nature, 286, 150-151 (1980).
54. Mizoguchi K, Tanaka Y, Tabira T. Anxiolytic effect of a herbal medicine, yokukansan, in aged rats: involvement of serotonergic and dopaminergic transmission in the prefrontal cortex. J. Ethnopharmacol., 127, 70-76 (2010).